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ABSTRACT
Androgen receptor (AR) variants (AR-Vs) expressed
in prostate cancer (PCa) lack the AR ligand binding
domain (LBD) and function as constitutively active
transcription factors. AR-V expression in patient tis-
sues or circulating tumor cells is associated with
resistance to AR-targeting endocrine therapies and
poor outcomes. Here, we investigated the mecha-
nisms governing chromatin binding of AR-Vs with
the goal of identifying therapeutic vulnerabilities.
By chromatin immunoprecipitation and sequencing
(ChIP-seq) and complementary biochemical experi-
ments, we show that AR-Vs display a binding prefer-
ence for the same canonical high-affinity androgen
response elements (AREs) that are preferentially en-
gaged by AR, albeit with lower affinity. Dimerization
was an absolute requirement for constitutive AR-V
DNA binding and transcriptional activation. Treat-
ment with the bromodomain and extraterminal (BET)
inhibitor JQ1 resulted in inhibition of AR-V chromatin
binding and impaired AR-V driven PCa cell growth
in vitro and in vivo. Importantly, this was associ-
ated with a novel JQ1 action of down-regulating AR-V
transcript and protein expression. Overall, this study
demonstrates that AR-Vs broadly restore AR chro-
matin binding events that are otherwise suppressed
during endocrine therapy, and provides pre-clinical
rationale for BET inhibition as a strategy for inhibit-
ing expression and chromatin binding of AR-Vs in
PCa.
INTRODUCTION
The androgen receptor (AR) is a steroid receptor transcrip-
tion factor that regulates the expression of genes required
for development and physiologic function of the prostate
gland (1). Additionally, AR transcriptional activity is fre-
quently co-opted by gene fusion events during prostate can-
cer (PCa) development and progression, as exemplified by
AR-dependent ERG overexpression caused by fusion of
the ERG gene body to the AR-regulated TMPRSS2 pro-
moter (2). Because of these important developmental and
gene fusion signaling roles, inhibiting AR transcriptional
activity is a highly effective therapy in patients with ad-
vanced PCa. This is achieved by blocking production of
androgens and competitive inhibition of the AR ligand
binding domain (LBD) with antiandrogens. While these en-
docrine therapies are initially effective, PCa will eventually
progress to a lethal, therapy-resistant disease stage termed
castration-resistant PCa (CRPC) (3–5). CRPC is associ-
ated with myriad alterations in the androgen/AR axis that
promote ongoing AR transcriptional activity. Newer an-
drogen synthesis inhibitors (abiraterone) and antagonists
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(enzalutamide) were developed to overcome several of the
mechanisms underlying persistent AR transcriptional ac-
tivity, and have been shown to extend overall survival of
patients with CRPC (6,7). However, there is evidence that
AR transcriptional activity may even resume in patients
treated with these second-generation therapies (8). Collec-
tively, these considerations signify a pressing need for more
durable AR inhibition strategies in CRPC.
One mechanism proposed to support persistent AR tran-
scriptional activity in CRPC is synthesis of constitutively
active AR variant (AR-V) proteins lacking the AR LBD
(9–13). Several AR-Vs have been identified and shown to
be translated from alternatively-spliced ARmRNAs, which
can be highly expressed in CRPC cells harboring structural
rearrangements in the AR gene (14–16). AR-Vs have been
shown to drive androgen-independent cell proliferation in a
manner that is resistant to antiandrogens, including enzalu-
tamide (17). Thus, AR-Vs represent a mechanism whereby
the growth of CRPC cells can remain AR-dependent, yet
uncoupled from endocrine regulation. Tumors that have
developed this mechanism of resistance are unlikely to re-
spond to successive generations of endocrine therapies. In-
deed, a recent prospective trial found that mRNA expres-
sion of the AR-V7 splice variant in tumor cells circulating
in the blood of CRPC patients was associated with primary
resistance to abiraterone and enzalutamide (18). These find-
ings indicate that AR-Vs could be attractive targets for ther-
apy of CRPC.
The absence of a LBD presents a formidable challenge
for direct inhibition of AR-Vs in CRPC because alternative
sites on the AR protein appropriate for specific and high-
affinity drug targeting are not evident. An indirect approach
may be through inhibition of AR-V transcriptional activa-
tion mechanisms. However, there is a paucity of informa-
tion regarding the molecular activity of AR-Vs in CRPC.
To address this limitation, we used chromatin immunopre-
cipitation followed by massively parallel sequencing (ChIP-
seq) and complementary biochemical approaches to under-
stand genome-wide AR-V DNA binding. We find that the
mechanisms governing AR-V chromatin interaction resem-
ble those of the prototypical androgen-activated AR: AR-
Vs bind DNA as a dimer and utilize canonical inverted
repeat androgen response elements (AREs). Moreover, we
demonstrate the bromodomain and extraterminal (BET)
family inhibitor JQ1 inhibits AR-V mRNA and protein
expression, thereby disrupting the AR-V:DNA interaction
and repressing the androgen-independent cell growth pro-
gram driven by AR-Vs.
MATERIALS AND METHODS
Cell lines and culture conditions
R1-AD1 and R1-D567 cells have been described (16).
LNCaP, 22Rv1, C4-2, 293T and COS-7 cells were obtained
from American Type Culture Collection (ATCC). R1AD1,
LNCaP, 22Rv1 and C4-2 cells were cultured in Roswell
Park Memorial Institute (RPMI) 1640 medium (Invitro-
gen) with 10% fetal bovine serum (FBS) and antibiotics
(100 units/ml penicillin and 100 mg/ml streptomycin). R1-
D567 cells were cultured in RPMI 1640 with 10% charcoal-
stripped FBS (CSS) and antibiotics. COS-7 cells and 293T
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) + 10% FBS and antibiotics. For androgen re-
sponse experiments, cells were electroporated, seeded in
RPMI 1640 containing 10% CSS for 48 h, and stimulated
for 24 h with serum free RPMI 1640 medium containing
1 nM mibolerone (Biomol) or dihydrotestosterone (DHT,
Sigma), orRPMI 1640 + 10%CSS containing various doses
of JQ1. PCa cell lines identities were validated by analysis of
signature AR gene alterations (14–16). Cells were cultured
in 37◦C incubators with 5% CO2 for no longer than 15 pas-
sages after resuscitation of frozen stocks.
Antibodies and siRNA reagents
siRNAs targeted to AR exon 1 (siAR1) and exon 3 (siAR2)
were purchased from Dharmacon. Antibodies were specific
for the AR NTD (Santa Cruz, N-20, #sc-816 or #sc-816X
for EMSAs, or Santa Cruz, 441, #sc-7305), ERK-2 (Santa
Cruz, D-2, #sc-1647), HA tag (Santa Cruz, F-7, #sc-7392),
BRD2 (Cell Signaling, #5848), the TSC2 COOH-terminal
domain (Cell Signaling #3612) or AR-V7 (Precision Anti-
body, #AG10008).
Plasmids
Plasmid and lentivirus constructs encoding full-length AR,
ARv567es, and AR-V7 (AR 1/2/3/CE3) have been de-
scribed (19). Luciferase reporters containing enhancer el-
ements for FASN AREI, II and III and TSC2 exon 37
ARE were constructed by isolating the desired genomic
sites by PCR with forward primers containing XhoI sites
and reverse primers containing BglII sites (Supplemental
Table S1), digestion with XhoI/BglII, and cloning into a
XhoI/BglII-digested pGL4.23minimal promoter luciferase
vector (Promega). Site directed mutagenesis of ARv567es
and AR-V7 expression vectors, as well as FASN AREI
and TSC2 ARE luciferase reporters, was performed using
a site-directed mutagenesis kit (Stratagene) and mutagenic
primers listed in Supplemental Table S1.
Control shRNA, shAR#1 or shAR#2 were expressed
using the lentiviral vector pLV-MSV40 (19). To gener-
ate these shRNA-expressing lentiviral constructs, oligonu-
cleotides (Supplemental Table S1) with the desired shRNA
sequences were synthesized such that annealing generated
64-mer cassettes with 5′ BglII and 3′ HindIII-compatible
ends for ligation downstream of the histone H1 pro-
moter in the BglII/HindIII-digested pCMS4-H1P-EGFP
vector, which has been described previously (20). These
H1 promoter/shRNA fragments were then liberated from
this vector by digestion with EcoRI/ClaI and ligated with
EcoR1/ClaI-digested pLV-MSV40.
The pLV-MSV40-HA vector was derived from pLV-
MSV40 by adding aHA tag downstream of SV40 promoter.
This was accomplished by PCR of the HA tag fragment
from a CMV5 vector with an N-terminal HA tag (21) us-
ing a forward primer harboring a Smal site and a reverse
primer harboring a SalI site, digestion with SmaI/SalI, and
ligation with EcoRV/SalI-digested pLV-VSV40. GFP and
AR-V7 fragments were excised from previously-described
pLV-MSV40 vectors (19) using EcoRV/SalI and sub-cloned
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Construction of transcription activator-like effector nu-
clease (TALEN) expression vectors targeting the FASN
AREI site (Supplemental Table S2) was performed by
Golden Gate cloning using the mammalian expression vec-
tor pC-GoldyTALEN (Addgene #38143) as described pre-
viously (16).
Multiplex ligation-dependent probe amplification (MLPA)
MLPA assays were performed as described previously (15).
Western blot
Western blots were performed as described (9). Briefly, blots
were incubated with primary antibodies overnight at 4◦C
and secondary antibodies at room temperature for 1 h.
Blots were incubated with Super Signal chemiluminescence
reagent (Pierce) and exposed to X-ray film.
ChIP-seq and ChIP-PCR
Chromatin immunoprecipitation (ChIP) with an antibody
specific for the AR NTD (AR-N20, Santa Cruz) was
performed for three independent biological replicate ex-
periments as described (22) with the following modifica-
tions: R1-AD1 and R1-D567 cells were seeded at 5 × 106
cells/plate on 10 cm plates in RMPI 1640 + 10% CSS, al-
lowed to settle for 72 h, then re-fed for 4h with RMPI 1640
+ 5% CSS containing vehicle (ETH) or 1 nMDHT prior to
fixation. Nuclear pellets were sonicated on ice for eight cy-
cles at 40% amplitude using a 450 Sonifer (Branson). Each
cycle consisted of 10 s pulse/10 s rests for 1 min, with 2 min
rests between cycles. Lysates were immunoprecipitated with
Protein A/G Plus agarose beads (Santa Cruz Biotechnol-
ogy) pre-blocked with tRNA (Sigma). DNA was purified
using a PCR purification kit (Qiagen). Alternatively, im-
munoprecipitated complexes were boiled in sodium dode-
cyl sulphate (SDS) loading buffer and subjected to west-
ern blot using a mouse monoclonal antibody specific for
the AR NTD (A441, Santa Cruz). For ChIP-seq, 10 ng of
DNA (ChIP-enriched or input) was used for library cre-
ation with a TruSeq ChIP Sample Preparation Kit (Illu-
mina cat. #IP-202-1012) and sequenced at the U of M Ge-
nomics Center using an Illumina HiSeq2000 at 1× 50 bp.
Mapping and processing of fastq files were performed in
Galaxy (23). Reads were mapped to hg19 with BWA (24)
using default parameters. SAMtools was used to remove
duplicate and non-uniquely mapping reads (MAPQ cutoff
15) (25). Peaks were called using data from biological repli-
cate 1 with two different software packages,MACS (26) and
CisGenome (27), using default parameters, a P value cutoff
of 1.00E−05 for both packages, and input DNA as nega-
tive control. Consensus peaks were determined by includ-
ing only regions identified by both peak callers; these peaks
were merged by using the inner coordinates of the overlap-
ping regions. ChIP-seq data are available through NCBI’s
Gene Expression Omnibus (GSE61838).
Compressed SRA files from ChIP-seq studies as-
sessing BRD2/3/4 chromatin occupancy in VCaP
((28), GSE55062) and H3K27Ac marks in VCaP ((28),
GSE55062) or LNCaP ((29), GSE27823) cells were con-
verted into fastq format using the fastq-dump utility within
the SRA toolkit (NCBI). For paired-end sequence data,
only read 1 was used for downstream analyses. Mapping
and processing of fastq files were performed in Galaxy (23)
exactly as described above for analysis of AR ChIP-seq
data from R1-AD1 and R1-D567 cells. AR and BRD2/3/4
peak files from VCaP cells (bed format) were a kind gift
from Dr Irfan Asangani.
Manipulation of intervals for analyzing overlaps between
different ChIP-seq datasets was performed in R 3.0.1 or us-
ing Galaxy. Cistrome (30) was used to quantitate conserva-
tion of peak sets and generate heatmaps using peak data in
.bed format and signal intensity data in wiggle format as in-
put. HOMER (31) and R were used to generate histograms
of tag density around peaks. Known androgen response ele-
ments (AREs) were identified in peak sets usingCisGenome
(27) with default parameters. Fold enrichment and signifi-
cance (Fisher’s exact test, calculated using R) of AREs in
the experimental peak sets were determined by comparisons
to control genomic regions with matched physical distribu-
tion. ARE position weight matrices were from the JASPAR
CORE vertebrata database (32), or a previous study identi-
fying AREs that are preferentially bound by wild-type AR
or an AR/GR hybrid (SPARKI AR, (33), a kind gift pro-
vided by Prof. O. Janne). Identification of de novo sequence
motifs in the peak sets was performed using the Gibbs Mo-
tif Sampling approach implemented in CisGenome (param-
eters altered from defaults: K = 10; mean motif length =
15), with enrichment and significance calculated as above.
The diffReps tool (34) run in G-test mode with default pa-
rameters was used to identify BRD2/3/4 binding sites that
were altered in VCaP cells by JQ1 treatment.
Visualization of ChIP-seq data at the gene-track level
was performed using Integrated Genomics Viewer (IGV
2.3, Broad Institute, (35)) and tdf files that had been gen-
erated from bam files using IGV Tools (default parame-
ters). For manual inspection of AR and ARv567es bind-
ing near genes identified in previous studies as being AR-V
‘unique’ (36,37), .bam files from three biological replicates
were merged to boost signal intensity.
BRD2 ChIP-PCR was performed exactly as AR ChIP-
seq and AR ChIP-PCR, with the exception that cells
were fixed with 1.5 mM of freshly prepared ethylene
glycolbis(succinimidylsuccinate) (EGS, Thermo Scientific
#51565) in 10 ml PBS at room temperature for 30 min.
For all ChIP-PCR experiments, DNA (ChIP-enriched or
input) was subjected to quantitative PCR using PerfeCTa
SYBR Green FastMix (Quanta Biosciences) and gene-
specific primers listed in Supplemental Table S1.
Luciferase reporter gene assays
R1-AD1, R1-D567 and LNCaP cells were electroporated
with 200 pmol siRNA or 12g plasmid DNA as de-
scribed (16,19). Electroporated cells were re-fed 48 h post-
transfection with serum-free medium containing 1 nM mi-
bolerone or DHT or 0.1% ethanol as vehicle control. Cells
were harvested after 24h of treatment and Dual Luciferase
Assays were performed using a kit (Promega) as per the
manufacturer’s recommendations. Data were normalized
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Transcription activator-like effector nuclease (TALEN)
genome editing
Cells were electroporated with 6g of left and right TAL-
ENs and seeded on 6-well plates in RMPI 1640 + 10%
CSS for 96 h. Genomic DNA was extracted using a Nucle-
ospin Tissue Kit (Machery-Nagel #740952). The TALEN-
targeted region was amplified by PCR using FASN-specific
primers (Supplemental Table S1), gel purified, and cloned
for Sanger sequencing or subjected to T7E1 endonuclease
assays. T7E1 assays were performed by incubating 400 ng
of PCR product in 1× NEBuffer 2 (New England Biolabs)
at 98◦C for 5 min, slowly cooling to room temperature, di-
gesting with 1 unit of T7 endonuclease 1 (NEB #M0302S)
at 37◦C for 1 h, and resolving products by electrophoresis
in 2% agarose gels.
Lentivirus transduction
Conditions for lentivirus virus packaging and cell transduc-
tion have been described (19).
Total RNA extraction and quantitative real time RT-PCR
Total RNA was isolated using TRIzol (Invitrogen) and
reverse-transcribed (Transcriptor First Strand cDNA Syn-
thesis kit, Roche Applied Science). Quantitative PCR was
performed with cDNA using PerfeCTa SYBR Green Fast-
Mix (Quanta Biosciences) with primer sets specific for
FASN, FKBP5, LIMA1, PSA, hK2 and GAPDH (Supple-
mental Table S1). Fold changes in mRNA expression lev-
els were calculated using the comparative Ct method as de-
scribed (19).
Electrophoretic mobility shift assay (EMSA)
IRD700-labled and competitor duplexes were prepared by
annealing complementary synthetic DNA oligonucleotides
(Supplemental Table S1). COS-7 cells growing on 10 cm
plates were transfected with empty vector or plasmids en-
coding AR, ARv567es or AR-V7 (AR 1/2/3/CE3) using
Lipofectamine 3000 (Invitrogen) according to the manu-
facturer’s recommendations. COS-7 cells transfected with
AR were stimulated with 1 nM mibolerone for 1hr prior
to nuclear extraction as described (38). Binding reactions
were carried out with 5 g nuclear extract and 2.5 nM of
IRD700-labeled FASN AREI duplex using an Odyssey In-
frared EMSA Kit (LI-COR # 829-07910) as per the man-
ufacturer’s recommendations. For competition assays, un-
labeled duplexes were added to binding reactions at 5 or
100molar excess. For binding saturation experiments, bind-
ing reactions were carried out by titrating IRD700-labeled
FASN AREI duplexes against a fixed 10 g of nuclear ex-
tract. Binding reactions were resolved in 4%polyacrylamide
gels with Tris-glycine electrophoresis buffer (50 mM Tris,
380 mM glycine, 2mM EDTA). Gels in glass plates were
scanned in an Odyssey scanner (LI-COR) at the 700 nm
channel. Images were captured and specific shift bands were
quantified using Image Studio software (LI-COR). Binding
saturation plots were developed using GraphPad Prism 5
software, with the apparent equilibrium dissociation con-
stants (Kd) defined as the concentration of IRD700-labeled
FASN AREI duplex required to achieve half-maximum
binding.
DNA duplex pull-down assay
Cells were cultured 72 h on 10 cm plates in RMPI 1640 +
10% CSS and stimulated with 1 nM DHT (R1-AD1 cells)
or vehicle (ethanol, R1-D567 cells) in RMPI 1640 + 5%
CSS for 4 h. Cells were lysed, cleared, and 500 g of pro-
tein lysates were used for DNA duplex pull-downs as de-
scribed (39) with 1 g of 5′ biotinylated duplex prepared by
annealing complementary synthetic DNA oligonucleotides
(Supplemental Table S1). Eluted proteins were analyzed by
western blot.
Gene set enrichment analysis (GSEA)
GSEA was performed using GSEA v2.07 (Broad Institute,
(40) using publicly-available datasets (R1-AD1 ± 1 nM
DHT = GSE49196, R1-D567 ± siARv567es = GSE49196,
LNCaP ± 1 nM DHT = GSE26483). A set of the top
100 genes up-regulated by treatment of LNCaP cells with
10 mM I-BET762, was obtained from a previous study
(41). This gene set, termed LNCaP 10uM UP (Supplemen-
tal Table S3) was tested for enrichment in gene expres-
sion data from R1-AD1 cells cultured 24 h in 1 nM DHT
versus ethanol vehicle control (NCBI gene expression om-
nibus GEO dataset GSE49169) (16), R1-D567 cells trans-
fected with control siRNA vs. siRNA targeting ARv567es
(GEO dataset GSE49169) (16), or LNCaP cultured 18
h in 1 nM DHT versus ethanol vehicle control (GEO
dataset GSE26483) using GSEA v2.07 (Broad Institute,
(40)). Genes were ranked using the Signal2Noise metric and
GSEAwas performed against 1000 random gene set permu-
tations.
Analysis of cell growth by crystal violet assay
Cells were seeded at a density of 5 × 104 cells/well
on 24-well plates, allowed to adhere to 48 h, and then
treated with JQ1. For experiments combining drug treat-
ment with lentiviral transduction, cells were seeded at 2 ×
104 cells/well on 24-well plates, allowed to adhere for 48 h,
and then transduced 24 h prior to treatment with JQ1. At
the indicated time points, cells were fixed and stained with
crystal violet as described (14).
Mouse xenograft assays
All protocols for mouse experiments were approved by the
U of M Institutional Care and Use Committee (IACUC).
For enzalutamide treatments, R1-AD1/R1-D567 cell mix-
tures were prepared by counting R1-AD1 and R1-D567
cells and mixing to achieve final cell number ratios of 90%
R1-AD1 and 10% R1-D567. Freshly-prepared admixtures
were suspended at 1 × 107cells/ml in 50% RPMI1640 sup-
plemented with 10% FBS and 50% Matrigel (BD Bio-
sciences) and 100 l was injected subcutaneously in the
right flank of male nude mice aged 6–7 weeks (Harlan Lab-
oratories). Tumor size was monitored twice a week by mea-
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formula length (mm) × width (mm) × height (mm). Af-
ter tumors reached 100 mm3, mice were anesthetized with
ketamine/xylazine (100mg/10mg/kg), a first tumor biopsy
was performed using a 1 mm biopsy punch (Miltex, Inc.
York, PA, USA), and then mice underwent surgical castra-
tion. Mice were treated with enzalutamide (Selleck Chemi-
cals) by daily oral gavage at 30 mg/kg/day for a total of 7
days. Subsequent tumor biopsies were performed on day 8
(end of enzalutamide therapy) and day 14 (two consecutive
tumor measurements displaying increased tumor size). On
day 16, the pre-defined study endpoint had been reached
(tumor volume≥ 1000 mm3), at which point mice were sac-
rificed and tumor tissue harvested.
For JQ1 treatments, 100 l of R1-D567 cell suspension
containing 1 × 107 cells/ml in 50% RPMI 1640 supple-
mented with 10% FBS and 50% Matrigel (BD Biosciences)
was injected subcutaneously in the right flank of 14 male
nude mice aged 6–7 weeks (Harlan Laboratories). After tu-
mors reached 100 mm3, mice were randomized by alternat-
ing assignments to control (DMSO, n = 7) or treatment
(JQ1, n = 7) groups, with 250 l DMSO or 50 mg/kg
JQ1 administered by intraperitoneal injection 5 days per
week for 4 consecutive weeks. Tumor size was monitored
twice a week and mice were euthanized when tumor vol-
ume reached 1000mm3, whichwas the pre-defined ‘survival’
endpoint for this study. Tumor growth rate and survival
analyses were performed using GraphPad Prism 5.0 soft-
ware (La Jolla, CA, USA).
RESULTS
Enzalutamide resistance in a treatment model of heteroge-
neous CRPC
AR-V-expressing tumor cells are common features of the
subclonal architecture of heterogeneous CRPC cell lines
and tissues, and have emerged as an important compo-
nent of resistance to endocrine therapies (10–12,15–18,42–
45). R1-D567 is a cell line harboring an engineered ge-
nomic deletion of AR exons 5–7, which was developed to
model an AR gene rearrangement discovered in hetero-
geneous CRPC tissue (15,16). Whereas the parental R1-
AD1 cell line expresses full-length AR, R1-D567 cells dis-
play exclusive expression of the constitutively active AR-V,
ARv567es (Figure 1A and B). To test the impact of AR-V-
expressing tumor cells on the therapeutic response of het-
erogeneous CRPC, we developed subcutaneous xenografts
with a 90%/10% mixture of R1-AD1/R1-D567 cells and
treated mice with a combination of castration and enzalu-
tamide (Figure 1C).
Western blot analysis of biopsied tumor tissue that had
been established in intact mice revealed that full-length AR
remained the predominant protein species (Figure 1C and
D). However, serially-sampled tumor tissue revealed enrich-
ment of ARv567es expression relative to full-length AR 6
days after initiation of treatment with enrichment continu-
ing through the study endpoint. DNA copy number analy-
sis via multiplex ligation-dependent probe amplification as-
say revealed that enrichment of ARv567es expression was
due to outgrowth of R1-D567 cells (Figure 1E). This in vivo
model highlights the importance of understanding the func-
tion and regulation of AR-Vs in CRPC, as this may reveal
opportunities for novel therapeutic interventions that in-
hibit AR-V activity and overcome therapeutic resistance.
ARv567es displays preferential genome-wide binding to
canonical AREs
We used the R1-AD1/R1-D567 model to study genome-
wide AR and ARv567es binding via ChIP-seq using an an-
tibody targeted to the AR NH2-terminal domain (NTD).
Peak calling with data from a single ChIP-seq experiment
resulted in the identification of 12 030 AR binding sites
in R1-AD1 cells and 3554 ARv567es binding sites in R1-
D567 cells (Figure 2A and B, Supplemental Table S4). Mo-
tif analysis revealed enrichment of canonical androgen re-
sponse elements (AREs) in both R1-AD1 and R1-D567
cells (Figure 2C, Supplemental Table S5). Further motif
analysis revealed that occurrences of stringent and relaxed
specificity AREs (33) were similar in both datasets (Supple-
mental Table S6). These data indicate that regulation of AR
and ARv567es DNA binding may proceed through similar
mechanisms.
Integration of R1-AD1 and R1-D567 ChIP-seq datasets
identified 1031 common genomic sites engaged by AR and
ARv567es (Figure 2A). These sites represented the highest-
affinity binding sites for both AR and ARv567es, although
the signal for ARv567es occupancy at these sites was lower
than for AR (Figure 2D). Occupancy of both factors at
these high-affinity sites was apparent in two additional in-
dependent biological replicate ChIP-seq experiments (Fig-
ure 2A). Examples of these high-affinity binding sites, which
were confirmed by ChIP-PCR, mapped to the FASN up-
stream regulatory region and exon 37 of the TSC2 gene
(Figure 3A–D). This approach also identified a set of 10 999
AR ‘unique’ binding sites, representing peaks called in R1-
AD1 but not R1-D567 cells (Figure 2A and D). However,
ChIP-seq heatmap plots of data from three independent bi-
ological replicate experiments provided evidence for weak
ARv567es occupancy at many of these sites (Figure 2A),
suggesting that at least some were false negatives (i.e. below
the threshold of detection of peak calling software). Indeed,
directed ChIP-PCR analysis of several of these AR ‘unique’
sites confirmed binding of ARv567es (Supplemental Figure
S1).
Integrative analysis of ChIP-seq data also identified a
putative set of 2523 ARv567es ‘unique’ binding sites in
R1-D567 cells (Supplemental Figure S2A). Inspection of
a subset of these sites where enrichment was highest for
ARv567es-specific signal revealed that most were located in
repetitive genomic elements, suggesting that at least some
were false positives (Supplemental Table S7). In line with
this, ARv567es-specific occupancy at these sites was not ob-
served in two independent biological replicate ChIP-seq ex-
periments (Supplemental Figure S2A). Further inspection
of ChIP-seq data at the gene-track level and directed ChIP-
PCR at representative ARv567es ‘unique’ sites that were
not within repetitive elements could not confirm ARv567es
binding (Supplemental Figure S3). Additionally, the puta-
tive ARv567es ‘unique’ sites lacked sequence conservation,
unlike common or AR ‘unique’ sites (Supplemental Figure
S2B). In aggregate, these findings strongly support the con-
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Figure 1. Outgrowth of AR-V expressing cells in a treatment model of heterogeneous CRPC. (A) Schematic representation of isogenic prostate cancer cell
lines R1-AD1 and R1-D567 expressing AR and ARv567es, respectively. (B) Western blots with R1-AD1 and R1-D567 lysates using antibodies specific
for the AR NTD and ERK-2 (loading control). (C) Schematic of treatment enrichment experiment. Xenografts were established in intact male mice
from a 90%/10% admixture of R1-AD1/R1-D567 cell lines. When tumors reached 100 mm3, mice were castrated and initiated 7-day treatment with 30
mg/kg/day enzalutamide by oral gavage. Biopsies of xenografts were collected at indicated days and the mice were euthanized when tumors reached 1000
mm3. (D) Western blot analysis of protein lysates from tumor tissue collected as in (C) probed with antibodies specific for the AR NTD and ERK-2
(loading control). (E) Multiplex ligation-dependent probe amplification (MLPA) with genomic DNA isolated from pre- and post-implantation samples.
Plots illustrate genomic copy number at indicated genomic locations across the AR gene.
tively active ARv567es closely resembles that of androgen-
activated AR.
The finding of similar AR and ARv567es genomic bind-
ing preferences is not in agreement with previous studies
reporting AR-V ‘unique’ transcriptional functions and/or
genomic binding specificity (11,37,46). To address this di-
rectly, we consolidated all mapped ChIP-seq reads from the
three biological replicates to boost signal intensity (yielding
over 80 × 106 mapped reads per condition), and used these
consolidated datasets to manually search for an ARv567es-
specific signal at 27 genes reported to be unique targets of
AR-Vs but not AR (36,37) (Supplemental Table S8). At
many of these candidate loci, recruitment of both AR and
ARv567es was apparent (for example, UBE2C and EDN2,
Supplemental Figure S4, A and B), while at other candi-
date loci recruitment of ARbut notARv567es was observed
(for example, ZWINT, Supplemental Figure S4C). How-
ever, across this entire set of reportedAR-V ‘unique’ targets,
in no case was an ARv567es-unique signal observed within
±100 kb of the candidate gene (Supplemental Table S8).
ARv567es activates canonical AREs
Because our data indicated that ARv567es displays a
genome-wide binding preference for canonical AREs, we
sought to understand the details of this bindingmechanism.
First, we tested the ability of common AR/ARv567es bind-
ing sites to enhance activity of a luciferase reporter regu-
lated by a minimal core promoter (Figure 3E). Of the three
discrete binding sites in the FASN upstream regulatory re-
gion, the site most proximal to the FASN transcription start
site, termed ARBSI, displayed robust androgen-responsive
enhancer activity in luciferase reporter assays (Figure 3E).
Knock-down of AR abolished androgen-mediated induc-
tion of the FASN-ARBSI reporter, as well as the reporter
regulated by the common AR/ARv567es binding site iden-
tified in exon 37 of the TSC2 gene (Figure 4A–C). Simi-
larly, knock-down of ARv567es in R1-D567 cells inhibited
androgen-independent activity of these reporters (Figure
4A–C).
Consistent with responsiveness to AR and ARv567es, a
consensus inverted repeat ARE, termed FASN-AREI, was
identified within FASN ARBSI (Figure 5A). To test the
functional importance of FASN-AREI within the context
of the endogenous gene locus, we designed transcription
activator-like effector nucleases (TALENs) to genomic se-
quences flanking FASN-AREI, which would result in tar-
getedDNAdouble-strand (dsDNA) breakswithin theARE
core sequence (Figure 5A). In R1-AD1 and R1-D567 cells
transfected with these TALENs, PCR of the target site
yielded efficient recovery of sequences displaying FASN-
AREI mutations caused by imprecise dsDNA break repair
(Figure 5A). Further analysis of these PCR products using
T7E1 nuclease heteroduplex assays indicated that TALEN-
mediated mutations occurred in approximately half of the
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Figure 2. Genome-wide binding of ARv567es to canonical AREs. (A) Heatmap of ChIP-seq signals± 3 kb aroundR1-AD1AR peakmidpoints from three
biological replicate experiments for a set of binding sites identified by peak calling with biological replicate 1 data as being common to dihydrotestosterone
(DHT)-treated R1-AD1 and vehicle (ethanol, ETH)-treated R1-D567 cells (upper panel), or ‘unique’ to R1-AD1 cells (lower panel). (B) Western blot of
chromatin processed for ChIP as in (A) probed with a monoclonal antibody specific for the AR NTD (AR441). (C) Sequence motifs enriched at AR (R1-
AD1) and ARv567es (R1-D567) binding sites identified de novo using the Gibbs Motif Sampling approach. (D) Average ChIP-seq tag intensities expressed
in mapped reads per base pair per peak normalized per 106 reads from three datasets at binding sites identified as common to R1-AD1 and R1-D567 cells,
or ‘unique’ to R1-AD1 cells.
these FASN AREI mutations reduced androgen-mediated
induction of FASN expression in R1-AD1 cells, as well
as constitutive androgen-independent FASN expression in
R1-D567 cells (Figure 5C).
A TALEN mutagenesis strategy was not pursued for an
ARE located in the TSC2 exon 37 ARBS, as it would lead
to mutations in TSC2 coding sequence. However, AR or
ARv567es knock-down in R1-AD1 or R1-D567 cells re-
sulted in decreased expression of the TSC2 short isoform
arising from transcription initiation within an alternative
internal promoter near this ARE site (Figure 5D), which
has been shown in a previous study to enhance LNCaP
proliferation (47). Additionally, treatment of androgen de-
pendent LNCaP cells with androgens or transduction with
lentivirus encoding ARv567es increased expression of the
TSC2 short isoform (Figure 5E).
AR-Vs bind and activate AREs through a dimerization-
dependent mechanism
Both the FASN AREI and the TSC2 exon 37 ARE are
canonical inverted repeats representative of AREs enriched
at genome-wide AR and ARv567es binding sites (Figure
2B). Point mutations disrupting either half site in these
AREs abolished androgen-mediated induction by AR in
R1-AD1 cells as well as androgen-independent induction
by ARv567es in R1-D567 cells (Figure 6A–D). These data
indicate that ARv567es binds genomic DNA through a
dimerization-dependent mechanism. To test whether this
was a general property of AR-Vs, we performed a simi-
lar set of assays with AR-V7, which harbors a different
COOH-terminal sequence compared with ARv567es, most
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Figure 3. Common AR/ARv567es binding sites function as androgen-responsive enhancers. (A) Gene track view of ChIP-seq data at the FASN locus.
Common AR/ARv567es binding sites (ARBS) are indicated. Data are from cells treated with dihydrotestosterone (DHT) or vehicle (ethanol, ETH) as
indicated. (B) Gene track view of ChIP-seq data at the TSC2 locus. A common AR/ARv567es binding site in TSC2 exon 37 is indicated. (C) Validation
of androgen-mediated recruitment of AR to FASN and TSC2 ARBSs in R1-AD1 cells by ChIP-qPCR. (D) Validation of constitutive ARv567es binding
to FASN and TSC2 ARBSs in R1-D567 cells by ChIP-qPCR. (E) FASN and TSC2 ARBSs were tested for enhancer response to the synthetic androgen
mibolerone (MIB) by luciferase reporter assay in R1-AD1 cells.
firmed binding of HA-tagged AR-V7 to FASN ARBS1
by ChIP-PCR (Figure 6E and F). Similar to ARv567es,
point mutations disrupting either half site of FASN ARE1
abolished androgen-independent induction by AR-V7 in
LNCaP cells (Figure 6G and H).
To further test the functional requirement for AR-V
dimerization, we generated A596T/S597T compound mu-
tations, which have been shown to disrupt the AR D-box
homodimer interface (48). Similar to ARE half-site muta-
tions, these mutations abolished transcriptional activity of
ARv567es and AR-V7 in LNCaP cells (Figure 6I). These
data indicate that dimerization is a general functional re-
quirement for AR-Vs. In agreement with this notion, AR
from R1-AD1 lysates and ARv567es from R1-D567 lysates
bound to a biotinylated DNA duplex with both FASN
AREI half-sites intact, but not to biotinylated DNA du-
plexes with mutations disrupting either half site (Figure 6J).
We next tested binding to the FASN AREI site by elec-
trophoreticmobility shift assays (EMSAs) with lysates from
COS-7 cells expressing ectopic AR andAR-Vs (Figure 7A).
Interestingly, this approach revealed that ARv567es and
AR-V7 bound to the FASNAREI site with respective equi-
librium dissociation constants (Kd) 2- and 4-fold lower than
full-length AR (Figure 7B and C). This lower affinity bind-
ing is consistent with the generally weaker signal observed
in ChIP-seq experiments for genome-wide ARv567es bind-
ing compared with full-length AR binding (Figure 2A and
D). For all AR species, FASN AREI binding was suscep-
tible to competition with an unlabeled FASN AREI se-
quence, but not FASN AREI sequences harboring muta-
tions in either half site (Figure 7D). From these data, we
conclude the predominant mode of AR-V binding to ge-
nomic DNA is through dimerization-dependent engage-
ment with the same canonical AREs engaged by full-length
AR. However, despite this being the predominant mode
of genome-wide binding, AR-Vs engage these canonical
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Figure 4. Common AR/ARv567es binding sites are AR/ARv567es-
dependent enhancers. (A) AR and ARv567es responsiveness of FASN
ARBSIwas tested by luciferase reporter assays inR1-AD1 andR1-D567es
cells transfected with control (CTRL) siRNA or two separate siRNAs tar-
geting AR. Cells were treated with 1 nM mibolerone (MIB) or ethanol
(ETH) as vehicle control as indicated. (B) AR and ARv567es responsive-
ness of TSC2 exon 37 ARBS was assessed as in (A). (C) Western blots with
R1-AD1 and R1-D567 lysates transfected as in (A) and (B) using antibod-
ies specific for the AR NTD and ERK-2 (loading control).
Down-regulation of AR and AR-V expression by BET inhi-
bition
Based on these mechanistic findings, we hypothesized that
disruption of AR-V:ARE interactions may represent a vi-
able strategy for overcoming AR-V-mediated therapeutic
resistance in CRPC. To develop preclinical support for
this chromatin targeting concept, we evaluated JQ1, an in-
hibitor of the BET family of chromatin readers (49) shown
to impair genome-wide chromatin binding and transcrip-
tional activation of androgen-activated full-length AR (28).
BET family chromatin readers BRD2, 3 and 4 engage
with acetylated lysine residues, including H3K27Ac, which
constitute chromatin marks enriched at active enhancers
and associated transcription start-sites of transcription-
ally active genes (50). As expected, JQ1 reduced androgen-
mediated AR engagement with FASN ARBSI in R1-AD1
cells (Figure 8A).More strikingly, JQ1 completely inhibited
constitutive AR-V engagement with this site in R1-D567
cells (Figure 8A). Unexpectedly, we noted loss of AR and
ARv567es protein when R1-AD1 and R1-D567 cells were
treated with therapeutically-relevant doses of JQ1 (28,49–
51), which corresponded with down-regulated AR mRNA
expression (Figure 8B and C). The CRPC C4-2, 22Rv1 and
VCaP cell lines also displayed dose-dependent reductions in
AR and/or AR-V expression in response to JQ1 treatment
(Figure 8B and C). In the LNCaP cell line, down-regulated
AR expression was observed for (+)-JQ1 but not (−)-JQ1,
indicating specificity for the active stereoisomer (Figure 8D)
(49).
To understand the basis for JQ1-mediated down-
regulation of AR expression, we analyzed publicly-available
ChIP-seq data from studies assessing genome-wide
H3K27Ac marks and the effects of JQ1 on BRD2, 3 and
4 binding in LNCaP and VCaP cells (28,29). Interestingly,
enrichment of H3K27Ac was evident near the transcription
start site of the AR gene, encompassing the 5′ untranslated
region (utr) and exon 1 (Figure 8E). Moreover, binding
of BRD2, 3 and 4 was apparent in this same region in
VCaP cells, with JQ1 treatment resulting in reduced signal
intensity for binding of BRD2, but not BRD3 or 4 (Figure
8E). Consistent with this finding, directed ChIP-PCR
analysis confirmed robust JQ1-mediated inhibition of
BRD2 binding to the AR 5′utr in R1-AD1 and R1-D567
cells (Figure 8F).
BET inhibitors impair AR and AR-V transcriptional activa-
tion and repression
In a previous study, the inhibitory effects of JQ1 on AR
chromatin binding were attributed to a direct interaction
between AR and BRD4 (28). We hypothesized our novel
finding of down-regulated AR and AR-V expression fol-
lowing JQ1 treatment represented an important compo-
nent of the JQ1 anti-AR mechanism of action, reminiscent
of down-regulated MYC expression in multiple myeloma
cells (50,51). To test this, we compared the effect of JQ1 on
AR chromatin binding in VCaP cells at AR binding sites
co-occupied by BRD4 (denoted AR+BRD4 sites), or AR
binding sites not occupied by BRD4 (denoted AR-BRD4
sites, Figure 9A). Whereas AR+BRD4 sites appeared to
be higher-affinity AR binding sites than AR-BRD4 sites,
JQ1 reduced AR binding by approximately 50% at both
of these sub-classes of AR binding sites (Figure 9B). In-
spection of specific AR+BRD4 and AR-BRD4 sites (which
included FASN-ARBSI and an AR binding site in intron
5 of FKBP5, respectively) confirmed that the presence of
H3K27Ac or BET family proteins was not required for JQ1-
mediated inhibition of AR binding (Figure 9C and D).
Next, we considered the possibility that the observed re-
duction in AR mRNA and protein levels could be a non-
selective result of the progressive, global decline in cellu-
lar mRNA expression that has been shown to ensue fol-
lowing BET inhibition (50). To test this, we focused on
a subset of genes that displayed paradoxical induction by
BET inhibitor treatment in AR-expressing PCa cells (Sup-
plemental Table S3) (41), hypothesizing these may represent
androgen/AR-repressed target genes. Because BET family
proteins are associated with transcriptionally active chro-
matin, but not transcriptionally repressed chromatin (50),
we postulated that induction (or de-repression) of these pu-
tative AR or AR-V repression targets by BET inhibitors
would signify functional selectivity of down-regulated AR
expression. Indeed, analysis of gene expression microarray
datasets using gene set enrichment analysis (40) demon-
strated that transcriptional programs of active AR or AR-
Vs were negatively enriched for a set of genes that were in-
duced in LNCaP cells upon treatment with the JQ1-related
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Figure 5. Common AR/ARv567es binding sites regulate endogenous transcriptional outcomes. (A) Schematic of TALENs targeted to an androgen re-
sponse element (ARE) in FASN ARBSI and examples of mutations recovered by PCR from TALEN-transfected R1-AD1 and R1-D567 cells. (B) T7E1
endonuclease assays evaluating frequency of mutations (assessed by T7E1 cleavage efficiency) in TALEN-transfected R1-AD1 and R1-D567 cells. (C)
Quantitative RT-PCR analysis of FASNmRNA levels in R1-AD1 and R1-D567 cells transfected with TALENs targeting FASNAREI or control (CTRL)
TALENs targeting an alternate genomic site. Cells were treated with dihydrotestosterone (DHT) or ethanol (ETH) as vehicle control as indicated. (D)
Western blots were performed with lysates of R1-AD1 (left) and R1-D567 (right) cells transfected with control (CTRL) siRNA or two separate siRNAs
targeting AR and treated with DHT or ETH as vehicle control as indicated. Blots were probed with antibodies specific for the COOH-terminal domain of
TSC2, the AR NTD or ERK-2 (loading control). Long and short forms of TSC2 are indicated. (E) Western blots were performed with lysates of LNCaP
cells transduced with lentivirus encoding GFP (control) or ARv567es and treated with a range of DHT concentrations (0.1, 1.0, 10 nM) or ethanol (‘–’,
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Figure 6. ARv567es binds canonical AREs through a dimerization-dependent mechanism. (A) ARE point mutations introduced in FASN ARBSI-LUC.
(B) Activities of constructs illustrated in (A) were tested in R1-AD1 and R1-D567 cells by luciferase assay. Cells were treated with 1 nMmibolerone (MIB)
or ethanol (ETH) as vehicle control as indicated. (C) ARE point mutations introduced in TSC2 exon 37-LUC. (D) Activities of constructs illustrated
in (C) were evaluated by luciferase assay as in (B). (E) Western blot of lysates from R1-AD1 cells transfected with HA-GFP and HA-AR-V7 for the
ChIP experiment shown in (F). (F) Constitutive recruitment of HA-tagged AR-V7 to the FASN ARBS1 site in transfected R1-AD1 cells was tested by
ChIP-PCR. Data represent fold enrichment of PCR signal in ChIP DNA isolated using an HA-directed antibody versus non-specific IgG control (which
was arbitrarily set to 1). (G) Activities of constructs illustrated in (A) were tested by luciferase assay using LNCaP cells transfected with an ARv567es
expression vector and treated with 1 nM mibolerone (MIB) or ethanol (ETH, vehicle) as indicated. (H) Activities of constructs illustrated in (A) were
tested by luciferase assay using LNCaP cells transfected with an AR-V7 expression vector exactly as described in (G). (I) Transcriptional activities of
wild-type and A596T/S597T D-box mutant versions of ARv567es and AR-V7 were tested in LNCaP cells by luciferase assay as described in (G). (J)
DNA duplex pull-down assays were performed by incubating biotinylated FASNAREI DNA duplexes harboring core sequences shown in A with cellular
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Figure 7. AR-Vs bind a canonical ARE with lower affinity than full-length AR. (A) Representative western blot of lysates from COS-7 cells transfected
with plasmids encoding AR, ARv567es and AR-V7 for EMSA experiments. The blot was probed with an antibody specific for the AR NTD. (B) Binding
of AR, ARv567es, and AR-V7 to an IRD700-labeled FASN AREI DNA duplex was assessed by electrophoretic mobility shift assay (EMSA). Supershifts
were achieved by adding an antibody specific for the AR NTD to binding reactions as indicated. (C) EMSAs were performed as in (B). Labeled FASN
AREI duplexes were titrated against a fixed 10 g of nuclear extract. Apparent equilibrium dissociation constants (Kd) are defined as the concentration of
FASN AREI duplex required to achieve half-maximum binding. (D) EMSAs were performed as in (B). Unlabeled competitor DNA duplexes harboring
wild-type or mutant FASN ARE1 core sequences shown in Figure 6A were added at 5× and 100× molar excess as indicated.
supported by quantitative RT-PCR, which demonstrated
that JQ1 impaired the ability of AR and ARv567es to re-
press expression of LIMA1 as well as activate expression
of FKBP5 and FASN (Figure 9F). Collectively, these re-
sults indicate that JQ1 has selectivity in down-regulating
AR and AR-V expression, which leads to reduced genome-
wide chromatin occupancy and coordinate inhibition of
these factors’ transcriptional activation and repression ac-
tivities. Therefore, inhibition of AR and AR-V expression
represents a previously-unknown, yet functionally impor-
tant, activity of BET inhibitors in PCa cells.
We next tested whether this novel anti-AR activity of
BET inhibition was associated with therapeutic efficacy
within the context of AR-V-driven CRPC. JQ1 treatment
inhibited androgen-dependent growth of R1-AD1 as well
as constitutive growth of R1-D567 cells, but the effect on
R1-D567 cells was more pronounced and occurred at lower
concentrations (Figure 10A). Additionally, the growth rate
of established R1-D567 xenograft tumors was reduced 1
week after initiating treatment of mice with JQ1, and con-
tinued treatment over 24 days extended the time to ex-
perimental endpoint (tumors reaching 1000 mm3) (Figure
10B). Collectively, these data provide preclinical evidence
that therapeutic resistance driven by AR-Vs can be over-
come with interventions that have selectivity in inhibiting
AR-V expression and genome binding activity.
DISCUSSION
AR-Vs are expressed widely in CRPC, and have been shown
to drive resistance to AR-targeted therapies in diverse cell-
and animal-based models (52). However, the mechanism of
AR-V-based resistance has been a subject of debate, likely
due to a lack of details regarding AR-V origin and func-
tion. In our previous work with heterogeneous CRPC tu-
mors and cell lines, we showed that high-level AR-V expres-
sion, either concurrent with or exclusive from full-length
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Figure 8. BET inhibitors repress expression of AR and ARv567es in prostate cancer cells. (A) Binding of full-length AR or ARv567es to FASN ARBS1
was tested in R1-AD1 or R1-D567 cells, respectively, treated with vehicle (DMSO) or JQ1 (0.5 mM) in the presence or absence of 1 nM dihydrotestosterone
(DHT) as indicated. (B) Western blots with antibodies specific for the AR NTD, AR-V7 or ERK-2 (loading control) with lysates from indicated PCa cell
lines treated 24 h with vehicle (DMSO) or JQ1 (doses: 0.1, 0.5, 1, 5, 10 M) in medium containing 10% CSS. (C) Quantitative RT-PCR analysis of total
AR mRNA levels in PCa cell lines treated as in (B). (D) Western blots with antibodies specific for the AR NTD or -actin (loading control) with lysates
from LNCaP cells treated 24 h with vehicle (DMSO) or active S(+) or inactive R(–) JQ1 stereoisomers as indicated. (E) Gene track view of BRD2, BRD3,
BRD4 and H3K27Ac ChIP-seq data at the AR locus. Data were obtained from NCBI Gene Expression Omnibus (GEO), representing VCaP cells treated
with 0.5 M JQ1 or vehicle control (DMSO) (GSE27823, (28)) or DHT-treated LNCaP cells (GSE27823, (29)). The FDR-adjusted P value signifying
JQ1-mediated loss of BRD2 binding at this site in VCaP cells was derived using diffReps (34). (F) Binding of BRD2 to the AR 5′utr region was tested in
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Figure 9. BET inhibitors coordinately suppress transcriptional activation and repression of AR and ARv567es target genes by reducing overall AR chro-
matin occupancy. (A) Venn diagram representing AR and BRD4 chromatin occupancy in VCaP cells. Occupancy data were obtained from a previous
study (28). (B) Average ChIP-seq tag intensities expressed in mapped reads per base pair per peak normalized per 106 reads from three datasets (VCaP
cells treated with vehicle, DHT, or DHT and JQ1) obtained from NCBI GEO (GSE27823, (28)). (C) Gene track views of AR, BRD2, BRD3, BRD4 and
H3K27Ac ChIP-seq data obtained from NCBI GEO (GSE27823, (28)) at the FASN locus. AR binding sites (ARBS) classified as co-occupied by AR and
BRD4 (AR+BRD4) are indicated. (D) Gene track views of the FKBP5 locus developed as in (C). An ARBS classified as occupied by AR but not BRD4
(AR-BRD4) is indicated. (E) Gene set enrichment analysis demonstrating that AR transcriptional activity in R1-AD1 and LNCaP cells, and ARv567es
transcriptional activity in R1-D567 cells, is negatively enriched for a set of I-BET762-induced genes. (F) Quantitative RT-PCR analysis of FKBP5, FASN
and LIMA1 mRNA expression in R1-AD1 and R1-D567 cells treated with combinations of vehicle (DMSO and ethanol, ETH), 0.5 M JQ1 or 1 nM












































































































Figure 10. Inhibition of AR-V-driven PCa cell growth by JQ1. (A) Growth
assays of R1-AD1 and R1-D567 cells in medium containing 10% FBS
(whole serum) or CSS (steroid-depleted serum) with increasing doses of
JQ1 (5 nM, 20 nM, 0.1 M, 0.5 M and 2 M). (B) Subcutaneous R1-
D567 xenograft tumors were established in intact male mice. When tumors
reached 100 mm3, mice were randomized to treatment (JQ1, n= 7) or con-
trol (DMSO, n= 7) groups for 24 days. Top: change in tumor volume from
day 7 to day 10 for DMSO versus JQ1 groups. Boxes represent first to third
quartiles with median; whiskers represent range. P values were derived us-
ing a two-tailed t-test. Bottom: Kaplan–Meier analysis of DMSO versus
JQ1 groups, representing time for tumors to reach 1000 mm3. P values
were derived using a log-rank (Mantel–Cox) test.
mor cells harboring underlying AR gene rearrangements
(15–17). Additional studies have shown acute increases in
AR-V mRNA and protein expression levels in response to
castration and treatment with AR antagonists (43,53).
A recent study of tumor cells circulating in the blood
of patients with CRPC found that mRNA expression of
the AR-V7 splice variant was associated with resistance
to abiraterone or enzalutamide (18). When quantitated,
AR-V7 mRNA levels were consistently increased in cir-
culating tumor cells collected post-treatment versus pre-
treatment (18). Moreover, several patients whose circulat-
ing tumor cells were negative for AR-V7 expression con-
verted to a positive AR-V7 expression profile during ther-
apy (18). The R1-AD1/R1-D567 xenograft model of het-
erogeneous CRPC employed in our study displayed sim-
ilar dynamic changes in AR-V expression during experi-
mental therapy, indicating thismodel could provide disease-
relevant insights to AR-V function in tumor progression.
To this end, the R1-AD1/R1-D567 model was used as an
exceptionally clean model system for comparing functions
of AR and a prototype AR-V, because both AR species are
expressed independently but from the same endogenousAR
locus. This model enabled the design of parallel ChIP-seq
workflows utilizing the same antibody, and allowed us to
avoid AR/AR-V knock-down or overexpression strategies.
ChIP-seq with this R1-AD1/R1-D567 model revealed that
ARv567es displayed a genome-wide binding preference for
high-affinity AREs, which are the same sites preferentially
bound by androgen-activatedAR.Using in vitro binding as-
says, we found that ARv567es and AR-V7 engagement with
these AREs was dimerization-dependent, requiring both
ARE half-sites and D-box residues in the second zinc fin-
ger of the AR DBD, which is also analogous to androgen-
activated AR (48,54)
It should be pointed out that a limitation of using the R1-
AD1/R1-D567 model was the inability to address the role
of potential interactions betweenAR andAR-Vs when they
are co-expressed in the same cell, including heterodimer-
ization on AREs. This will be important for future stud-
ies, especially given the discrepant reports in the literature
on whether AR and AR-Vs heterodimerize when they are
co-expressed (12,55). In this respect, the current study pro-
vides an important baseline, providing strong evidence for
the notion that AR-Vs independently support therapeutic
resistance in CRPC by recapitulating AR chromatin bind-
ing events that are otherwise lost or suppressed during en-
docrine therapy. This is also in agreement with microarray-
based experiments, which have shown that AR-Vs can sup-
port constitutive expression of the broad androgen/AR
transcriptional program (16,17).
Interestingly, an additional property that has been as-
cribed to AR-Vs is the regulation of a distinct subset of
transcriptional targets that would be expected to provide
a higher proliferative capacity and/or tumorigenic advan-
tage to AR-V-expressing cells (36). Distinct AR-V tran-
scriptional targets have been proposed to be the result of
distinct AR-V chromatin binding sites (10,37,46,56). How-
ever, our genome-wide ChIP-seq analyses as well as direct
interrogation of candidate loci (including UBE2C, a target
that prior studies deemed to be unique to AR-Vs) did not
provide support for the concept of distinct genomic AR-V
binding sites. Nevertheless, our data do not completely rule
out the existence of AR-V-specific gene targets for two key
reasons. First, the levels of ARv567es protein expressed in
steroid deplete R1-D567 cells are lower than the levels of
ARprotein expressed in steroid repleteR1-AD1 cells, which
biased ChIP-seq sensitivity in favor of AR binding events.
Second, this bias was likely exacerbated by the lower affin-
ity of AR-Vs relative to AR for high-affinity AREs, which
could be due to loss of stabilizing interactions between the
ARLBD andDBD (57). Despite these limitations, our data
strongly suggest that any distinct genomic AR-V binding
events, if they do indeed exist, are not among the predom-
inant AR-V binding events in CRPC cells. Technical opti-
mization will be required if these putative minor sites are to
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The absence of a LBDpresents a formidable challenge for
direct inhibition of AR-Vs in CRPC. Our work has high-
lighted the low-affinity AR-V:ARE interaction as a poten-
tial vulnerability that could be exploited to interfere with
constitutive AR-V function. JQ1, which inhibits the epige-
netic reader function of BET family proteins, has increased
potency in AR-driven PCa cell lines compared with AR-
independent PCa cell lines (28,41). This was shown to be
the result of direct interactions between BRD4 and the
AR NH2-terminal domain, leading to genome-wide JQ1-
mediated inhibition of AR binding to chromatin enhancers
and impaired androgen induction of downstream targets
(41). However, BET family proteins display only 10% over-
lap in binding with genomic AR binding sites (41), which
appears to be at least partially inconsistent with the abil-
ity of JQ1 to block the broad androgen/AR transcriptional
program. Our data revealing that BET inhibition down-
regulates AR expression and thereby inhibits AR chro-
matin binding even at sites not associated with BET fam-
ily proteins could potentially explain this discrepancy. In
particular, this finding provides a logical mechanism for
the observed dual actions of BET inhibitors repressing
AR-activated genes and de-repressing AR-repressed genes.
Mechanistically, we observed enrichment of H3K27Ac and
BRD2, 3 and 4 near the transcription start site of the AR
gene, which are chromatin features shared with other genes
that display disproportionate sensitivity to JQ1 including
MYC and CCND2 (50,51). Moreover, we found that treat-
ment with JQ1 disrupted BRD2 binding to the AR 5′utr,
which provides initial evidence for AR gene regulation by
BRD2.
In conclusion, this study describes a therapeutic resis-
tance mechanism in CRPC whereby AR-Vs constitutively
engage and transcriptionally regulate canonical AREs as
dimers. This study further provides pre-clinical proof-of-
principle that challenges inherent with direct targeting of
AR-Vs may be overcome by indirect targeting of AR-V ex-
pression and/or chromatin binding. Moreover, this study
offers important insights into BET inhibitors in CRPC
cells, most notably revealing down-regulation of AR and
AR-V expression as a novel component of their anti-AR
mechanism-of-action. This desirable activity is not achieved
by any AR-targeted drugs currently in clinical use, which
provides additional rationale for developing BET inhibitors
as therapeutics for advanced PCa.
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